Phase 1 Stomach Cancer Trial, Recruiting NCT06010862 Sponsor: Chongqing Precision Biotech Co., Ltd Condition: Stomach Cancer
Back to Stomach Cancer

Phase 1 Stomach Cancer Trial, Recruiting

NCT06010862
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been diagnosed with an advanced, spreading, or returning cancer (mainly colorectal, esophageal, stomach, or pancreatic cancer) confirmed by a tissue or lab test
  • Your cancer has continued to grow or you could not tolerate at least two rounds of standard treatments (such as surgery, chemotherapy, or radiation), or there are no effective treatments available to you
  • A recent tumor sample (within the last 3 months) shows a protein called CEA on at least 10% of cancer cells, and/or your blood CEA level is above 10 µg/L (confirm with trial site)
  • You have at least one measurable tumor that can be tracked during the trial
  • You are reasonably active and able to care for yourself (your doctor will assess this using a standard scale)
  • You do not have a serious mental health condition
  • Your blood counts, heart, kidneys, liver, and blood oxygen levels meet certain minimum health requirements (the trial team will check these with tests)
  • Your veins are suitable for a blood collection procedure needed to make the treatment
  • You agree to use reliable contraception for up to one year after receiving the treatment
  • You (or your legal guardian) agree to take part and sign a consent form after understanding what the trial involves

Who may not be able to join:

  • Your cancer has spread to the brain or the lining around the brain and the doctor considers this a concern
  • You have taken part in another clinical trial within the last month
  • You received a live vaccine (such as certain flu or travel vaccines) within the last 4 weeks
  • You received chemotherapy, targeted therapy, or other experimental cancer treatments within the last 14 days (or within a certain number of half-lives of the drug — confirm with trial site)
  • You have an active or uncontrolled infection that requires treatment
  • You currently have a blocked bowel, active bleeding in your digestive system, or had digestive bleeding within the past 3 months
  • You still have significant side effects from previous cancer treatments (apart from hair loss or mild nerve-related issues) that have not returned to near-normal levels
  • You have a serious heart condition, including severe heart failure, a heart attack or bypass surgery within the last 6 months, significant irregular heartbeat, unexplained fainting, or a history of serious heart muscle disease
  • You have an active autoimmune disease or need long-term medication to suppress your immune system
  • You have had another type of cancer in the past 3 years (except certain early-stage skin or cervical cancers)
  • You have active hepatitis B, hepatitis C, HIV, or syphilis based on blood tests
  • You are pregnant or breastfeeding
  • The trial doctor decides for any other reason that the trial is not appropriate for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Fei Li, M.D, The First Affiliated Hospital of Nanchang University

Phone: 13970038386

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Chongqing Precision Biotech Co., Ltd
Registry
ClinicalTrials.gov
Start date
30 September 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Adverse events after CEA CAR-T cells infusion [Safety and Tolerability]; Obtain the maximum tolerated dose of CEA CAR-T cells[Safety and Tolerability]

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov